Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum-Reference-Cited by-同舟云学术

Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum

Published:2022-01 Issue:1 Volume:14 Page:
ISSN:2352-8729
Container-title:Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
language:en
Short-container-title:Alz & Dem Diag Ass & Dis Mo

Author:

Doré Vincent¹²^ORCID,Doecke James D.³,Saad Ziad S.⁴,Triana‐Baltzer Gallen⁴,Slemmon Randy⁴,Krishnadas Natasha²,Bourgeat Pierrick³,Huang Kun²,Burnham Samantha¹,Fowler Christopher⁵,Rainey‐Smith Stephanie R.⁶,Bush Ashley I.⁵⁷,Ward Larry⁵,Robertson Jo⁵,Martins Ralph N.⁶⁸⁹,Masters Colin L.⁵,Villemagne Victor L.²¹⁰,Fripp Jurgen³,Kolb Hartmuth C.⁴,Rowe Christopher C.²⁵⁷

Affiliation:

1. The Australian e‐Health Research Centre CSIRO Melbourne Victoria Australia

2. Department of Molecular Imaging & Therapy Austin Health Melbourne Victoria Australia

3. The Australian e‐Health Research Centre CSIRO Brisbane Queensland Australia

4. Neuroscience Biomarkers Janssen Research and Development La Jolla California USA

5. The Florey Institute of Neuroscience and Mental Health Melbourne Victoria Australia

6. Edith Cowan University Joondalup Western Australia Australia

7. Florey Department of Neuroscience and Mental Health The University of Melbourne Melbourne Victoria Australia

8. Centre for Healthy Ageing, Health Futures Institute Murdoch University Murdoch Western Australia Australia

9. McCusker Alzheimer's Research Foundation Nedlands Western Australia Australia

10. Department of Psychiatry University of Pittsburgh Pittsburgh Pennsylvania USA

Funder

National Health and Medical Research Council

Publisher

Wiley

Subject

Psychiatry and Mental health,Neurology (clinical)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/dad2.12307

Reference36 articles.

1. Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical Trials

2. High performance plasma amyloid-β biomarkers for Alzheimer’s disease

3. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts

4. Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration

5. Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical value of plasma ALZpath pTau217 immunoassay in the assessment of mild cognitive impairment;2024-01-22

2. Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies;JAMA Neurology;2024-01-01

3. Plasma pTau‐217 and N‐terminal tau (NTA) enhance sensitivity to identify tau PET positivity in amyloid‐β positive individuals;Alzheimer's & Dementia;2023-11-03

4. Application of Deep Learning for Prediction of Alzheimer’s Disease in PET/MR Imaging;Bioengineering;2023-09-24

5. Blood-based biomarkers for Alzheimer’s disease: Current state and future use in a transformed global healthcare landscape;Neuron;2023-09